Cryo-Cell International, Inc. 10-Q Summary
Business Context and Reporting Period
Cryo-Cell International, Inc. is engaged in the cellular processing and cryogenic storage of umbilical cord blood stem cells. This report covers the quarterly period ended August 31, 2007, and the nine-month period ended on the same date. The company operates primarily in the United States with international licensing agreements.
Key Financial Metrics
| Metric | Nine Months Ended Aug 31, 2007 | Nine Months Ended Aug 31, 2006 |
|---|---|---|
| Revenue | $13,173,166 | $12,760,760 |
| Net Loss | $(3,338,062) | $(1,884,153) |
| Loss Per Share (Basic & Diluted) | $(0.29) | $(0.16) |
| Operating Cash Flow | $(3,083,408) | $640,582 |
| Cash and Cash Equivalents (End of Period) | $3,747,166 | $7,630,673 |
| Total Assets | $12,035,744 | $14,640,383 |
| Stockholders' Deficit | $(5,035,174) | $(2,092,146) |
Debt and Liquidity: As of August 31, 2007, the company reported no indebtedness. However, it carries significant long-term liabilities related to Revenue Sharing Agreements (RSAs) totaling $3,750,000 and deferred consulting obligations of $492,612. The company maintains a stockholders' deficit of approximately $5.0 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 3% year-over-year to $13.17 million, driven by a 17% increase in storage fees and price increases for new clients, partially offset by an 8% decrease in specimens processed.
- Expense Increases: Net loss widened significantly (77% increase) due to a 14% rise in Marketing, General & Administrative (MG&A) expenses and a 88% increase in R&D expenses.
- Specific Cost Drivers:
- Proxy Contest: Approximately $580,000 in professional fees were incurred related to a dissident shareholder proxy contest.
- Accounting Change: Adoption of SFAS 123R resulted in approximately $194,000 in stock-based compensation expense.
- R&D: Increased spending of $481,000 related to new product development, specifically maternal placental stem cells (MPSCs).
- Cash Flow Deterioration: Operating cash flow swung from a positive $640,582 in the prior year to a negative $3.08 million. This was driven by the net loss, increased receivables due to in-house financing plans (since discontinued), and payments for prior year equipment and courier services.
Outlook, Risks, and Management Commentary
- Product Launch Postponement: In April 2007, the company indefinitely postponed the commercial launch of its fetal placental stem cell service (Plureon) due to technological commercialization considerations.
- Liquidity Outlook: Management anticipates that current cash, marketable securities ($1.06 million), and operating cash flows will be sufficient to fund operations for at least the next 12 months. Capital expenditures for fiscal 2007 are estimated at $750,000.
- Legal Proceedings:
- PharmaStem Litigation: The Federal Circuit Court upheld a judgment in Cryo-Cell's favor, ruling PharmaStem's patents invalid. PharmaStem may petition the Supreme Court by December 3, 2007.
- Shareholder Litigation: A lawsuit filed by David Portnoy regarding the 2007 Annual Meeting and director elections is scheduled for trial in November 2007.
- Contingencies: The company maintains a reserve of $63,843 for its "Cryo-Cell Cares" product guarantee program, which covers potential engraftment failures. No claims have been made to date.
Investor Verification Checklist
- Verify the status of the Supreme Court petition regarding the PharmaStem patent litigation.
- Monitor the outcome of the shareholder lawsuit filed by David Portnoy regarding board elections.
- Assess the impact of the indefinite postponement of the placental stem cell service on future revenue growth projections.
- Review the sustainability of the cash burn rate given the negative operating cash flow of $3.08 million for the nine-month period.
- Confirm the collectibility of accounts receivable, which increased by $1.17 million during the period due to financing plans.